Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Targeting Treatments to Improve Cognitive Function in Mood Disorder : Suggestions From Trials Using Erythropoietin. / Miskowiak, Kamilla Woznica; Rush, A. John; Gerds, Thomas A.; Vinberg, Maj; Kessing, Lars V.

In: Journal of Clinical Psychiatry, Vol. 77, No. 12, 12.2016, p. e1639–e1646.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Miskowiak, KW, Rush, AJ, Gerds, TA, Vinberg, M & Kessing, LV 2016, 'Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin', Journal of Clinical Psychiatry, vol. 77, no. 12, pp. e1639–e1646. https://doi.org/10.4088/JCP.15m10480

APA

Miskowiak, K. W., Rush, A. J., Gerds, T. A., Vinberg, M., & Kessing, L. V. (2016). Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. Journal of Clinical Psychiatry, 77(12), e1639–e1646. https://doi.org/10.4088/JCP.15m10480

Vancouver

Miskowiak KW, Rush AJ, Gerds TA, Vinberg M, Kessing LV. Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. Journal of Clinical Psychiatry. 2016 Dec;77(12):e1639–e1646. https://doi.org/10.4088/JCP.15m10480

Author

Miskowiak, Kamilla Woznica ; Rush, A. John ; Gerds, Thomas A. ; Vinberg, Maj ; Kessing, Lars V. / Targeting Treatments to Improve Cognitive Function in Mood Disorder : Suggestions From Trials Using Erythropoietin. In: Journal of Clinical Psychiatry. 2016 ; Vol. 77, No. 12. pp. e1639–e1646.

Bibtex

@article{f0b684fef6064a8093baac557d5f05a5,
title = "Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin",
abstract = "OBJECTIVE: There is no established efficacious treatment for cognitive dysfunction in unipolar and bipolar disorder. This may be partially due to lack of consensus regarding the need to screen for cognitive impairment in cognition trials or which screening criteria to use. We have demonstrated in 2 randomized placebo-controlled trials that 8 weeks of erythropoietin (EPO) treatment has beneficial effects on verbal memory across unipolar and bipolar disorder, with 58{\%} of EPO-treated patients displaying a clinically relevant memory improvement as compared to 15{\%} of those treated with placebo.METHODS: We reassessed the data from our 2 EPO trials conducted between September 2009 and October 2012 to determine whether objective performance-based memory impairment or subjective self-rated cognitive impairment at baseline was related to the effect of EPO on cognitive function as assessed by Rey Auditory Verbal Learning Test (RAVLT) total recall with multiple logistic regression adjusted for diagnosis, age, gender, symptom severity, and education levels.RESULTS: We included 79 patients with an ICD-10 diagnosis of unipolar or bipolar disorder, of whom 39 received EPO and 40 received placebo (saline). For EPO-treated patients with objective memory dysfunction at baseline (n = 16) (defined as RAVLT total recall ≤ 43), the odds of a clinically relevant memory improvement were increased by a factor of 290.6 (95{\%} CI, 2.7-31,316.4; P = .02) compared to patients with no baseline impairment (n = 23). Subjective cognitive complaints (measured with the Cognitive and Physical Functioning Questionnaire) and longer illness duration were associated with small increases in patients' chances of treatment efficacy on memory (53{\%} and 16{\%} increase, respectively; P ≤ .04). Diagnosis, gender, age, baseline depression severity, and number of mood episodes did not significantly change the chances of EPO treatment success (P ≥ .06). In the placebo-treated group, the odds of memory improvement were not significantly different for patients with or without objectively defined memory dysfunction (P ≥ .59) or subjective complaints at baseline (P ≥ .06).CONCLUSIONS: Baseline objectively assessed memory impairments and-to a lesser degree-subjective cognitive complaints increased the chances of treatment efficacy on cognition in unipolar and bipolar disorder.TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00916552.",
author = "Miskowiak, {Kamilla Woznica} and Rush, {A. John} and Gerds, {Thomas A.} and Maj Vinberg and Kessing, {Lars V.}",
year = "2016",
month = "12",
doi = "10.4088/JCP.15m10480",
language = "English",
volume = "77",
pages = "e1639–e1646",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press, Inc",
number = "12",

}

RIS

TY - JOUR

T1 - Targeting Treatments to Improve Cognitive Function in Mood Disorder

T2 - Suggestions From Trials Using Erythropoietin

AU - Miskowiak, Kamilla Woznica

AU - Rush, A. John

AU - Gerds, Thomas A.

AU - Vinberg, Maj

AU - Kessing, Lars V.

PY - 2016/12

Y1 - 2016/12

N2 - OBJECTIVE: There is no established efficacious treatment for cognitive dysfunction in unipolar and bipolar disorder. This may be partially due to lack of consensus regarding the need to screen for cognitive impairment in cognition trials or which screening criteria to use. We have demonstrated in 2 randomized placebo-controlled trials that 8 weeks of erythropoietin (EPO) treatment has beneficial effects on verbal memory across unipolar and bipolar disorder, with 58% of EPO-treated patients displaying a clinically relevant memory improvement as compared to 15% of those treated with placebo.METHODS: We reassessed the data from our 2 EPO trials conducted between September 2009 and October 2012 to determine whether objective performance-based memory impairment or subjective self-rated cognitive impairment at baseline was related to the effect of EPO on cognitive function as assessed by Rey Auditory Verbal Learning Test (RAVLT) total recall with multiple logistic regression adjusted for diagnosis, age, gender, symptom severity, and education levels.RESULTS: We included 79 patients with an ICD-10 diagnosis of unipolar or bipolar disorder, of whom 39 received EPO and 40 received placebo (saline). For EPO-treated patients with objective memory dysfunction at baseline (n = 16) (defined as RAVLT total recall ≤ 43), the odds of a clinically relevant memory improvement were increased by a factor of 290.6 (95% CI, 2.7-31,316.4; P = .02) compared to patients with no baseline impairment (n = 23). Subjective cognitive complaints (measured with the Cognitive and Physical Functioning Questionnaire) and longer illness duration were associated with small increases in patients' chances of treatment efficacy on memory (53% and 16% increase, respectively; P ≤ .04). Diagnosis, gender, age, baseline depression severity, and number of mood episodes did not significantly change the chances of EPO treatment success (P ≥ .06). In the placebo-treated group, the odds of memory improvement were not significantly different for patients with or without objectively defined memory dysfunction (P ≥ .59) or subjective complaints at baseline (P ≥ .06).CONCLUSIONS: Baseline objectively assessed memory impairments and-to a lesser degree-subjective cognitive complaints increased the chances of treatment efficacy on cognition in unipolar and bipolar disorder.TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00916552.

AB - OBJECTIVE: There is no established efficacious treatment for cognitive dysfunction in unipolar and bipolar disorder. This may be partially due to lack of consensus regarding the need to screen for cognitive impairment in cognition trials or which screening criteria to use. We have demonstrated in 2 randomized placebo-controlled trials that 8 weeks of erythropoietin (EPO) treatment has beneficial effects on verbal memory across unipolar and bipolar disorder, with 58% of EPO-treated patients displaying a clinically relevant memory improvement as compared to 15% of those treated with placebo.METHODS: We reassessed the data from our 2 EPO trials conducted between September 2009 and October 2012 to determine whether objective performance-based memory impairment or subjective self-rated cognitive impairment at baseline was related to the effect of EPO on cognitive function as assessed by Rey Auditory Verbal Learning Test (RAVLT) total recall with multiple logistic regression adjusted for diagnosis, age, gender, symptom severity, and education levels.RESULTS: We included 79 patients with an ICD-10 diagnosis of unipolar or bipolar disorder, of whom 39 received EPO and 40 received placebo (saline). For EPO-treated patients with objective memory dysfunction at baseline (n = 16) (defined as RAVLT total recall ≤ 43), the odds of a clinically relevant memory improvement were increased by a factor of 290.6 (95% CI, 2.7-31,316.4; P = .02) compared to patients with no baseline impairment (n = 23). Subjective cognitive complaints (measured with the Cognitive and Physical Functioning Questionnaire) and longer illness duration were associated with small increases in patients' chances of treatment efficacy on memory (53% and 16% increase, respectively; P ≤ .04). Diagnosis, gender, age, baseline depression severity, and number of mood episodes did not significantly change the chances of EPO treatment success (P ≥ .06). In the placebo-treated group, the odds of memory improvement were not significantly different for patients with or without objectively defined memory dysfunction (P ≥ .59) or subjective complaints at baseline (P ≥ .06).CONCLUSIONS: Baseline objectively assessed memory impairments and-to a lesser degree-subjective cognitive complaints increased the chances of treatment efficacy on cognition in unipolar and bipolar disorder.TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00916552.

U2 - 10.4088/JCP.15m10480

DO - 10.4088/JCP.15m10480

M3 - Journal article

C2 - 27835716

VL - 77

SP - e1639–e1646

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -

ID: 171587328